XML 89 R51.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment and Geographic Information (Tables) | 12 Months Ended
--- | ---
Apr. 25, 2025
Segment Reporting [Abstract] |
Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated | Segment Operating Profit
| Fiscal Year 2025
(in millions) | Cardiovascular |  | Neuroscience |  | Medical Surgical |  | Diabetes |  | Total
Net sales | $ | 12,481 |  |  | $ | 9,846 |  |  | $ | 8,407 |  |  | $ | 2,755 |  |  | $ | 33,489 |
Reconciliation of revenues |  |  |  |  |  |  |  |  |
Other operating segment net sales (1) |  |  |  |  |  |  |  |  | 137 |
Other adjustments (2) |  |  |  |  |  |  |  |  | (90) |
Total consolidated net sales |  |  |  |  |  |  |  |  | $ | 33,537 |
Less: |  |  |  |  |  |  |  |  |
Cost of products sold, excluding amortization of intangible assets | 3,967 |  |  | 2,762 |  |  | 3,142 |  |  | 1,117 |  |  | 10,987 |
Research and development expense | 931 |  |  | 542 |  |  | 606 |  |  | 400 |  |  | 2,478 |
Selling, general, and administrative expense | 2,824 |  |  | 2,327 |  |  | 1,600 |  |  | 791 |  |  | 7,541 |
Other segment items (3) | (41) |  |  | 31 |  |  | 18 |  |  | (43) |  |  | (36) |
Reportable segment operating profit | $ | 4,801 |  |  | $ | 4,183 |  |  | $ | 3,042 |  |  | $ | 491 |  |  | $ | 12,518 |
Reconciliation of segment profit / (loss) |  |  |  |  |  |  |  |  |
Other operating segment profit (1) |  |  |  |  |  |  |  |  | 49 |
Corporate |  |  |  |  |  |  |  |  | (1,837) |
Interest expense, net |  |  |  |  |  |  |  |  | (729) |
Other non-operating income, net |  |  |  |  |  |  |  |  | 402 |
Amortization of intangible assets |  |  |  |  |  |  |  |  | (1,807) |
Stock-based compensation |  |  |  |  |  |  |  |  | (429) |
Centralized distribution costs |  |  |  |  |  |  |  |  | (1,650) |
Currency |  |  |  |  |  |  |  |  | (3) |
Restructuring and associated costs |  |  |  |  |  |  |  |  | (303) |
Acquisition and divestiture-related items |  |  |  |  |  |  |  |  | (124) |
Certain litigation charges, net |  |  |  |  |  |  |  |  | (317) |
Medical device regulations |  |  |  |  |  |  |  |  | (52) |
Other adjustments (2) |  |  |  |  |  |  |  |  | (90) |
Income before income taxes |  |  |  |  |  |  |  |  | $ | 5,628 |
| Fiscal Year 2024
(in millions) | Cardiovascular |  | Neuroscience |  | Medical Surgical |  | Diabetes |  | Total
Net sales | $ | 11,831 |  |  | $ | 9,406 |  |  | $ | 8,417 |  |  | $ | 2,488 |  |  | $ | 32,142 |
Reconciliation of revenues |  |  |  |  |  |  |  |  |
Other operating segment net sales (1) |  |  |  |  |  |  |  |  | 221 |
Total consolidated net sales |  |  |  |  |  |  |  |  | $ | 32,364 |
Less: |  |  |  |  |  |  |  |  |
Cost of products sold, excluding amortization of intangible assets | 3,731 |  |  | 2,634 |  |  | 3,057 |  |  | 963 |  |  | 10,385 |
Research and development expense | 906 |  |  | 556 |  |  | 587 |  |  | 402 |  |  | 2,452 |
Selling, general, and administrative expense | 2,748 |  |  | 2,245 |  |  | 1,594 |  |  | 778 |  |  | 7,365 |
Other segment items (3) | (28) |  |  | 30 |  |  | 9 |  |  | (49) |  |  | (39) |
Reportable segment operating profit | $ | 4,474 |  |  | $ | 3,940 |  |  | $ | 3,170 |  |  | $ | 394 |  |  | $ | 11,979 |
Reconciliation of segment profit / (loss) |  |  |  |  |  |  |  |  |
Other operating segment profit (1) |  |  |  |  |  |  |  |  | 10 |
Corporate |  |  |  |  |  |  |  |  | (1,784) |
Interest expense, net |  |  |  |  |  |  |  |  | (719) |
Other non-operating income, net |  |  |  |  |  |  |  |  | 412 |
Amortization of intangible assets |  |  |  |  |  |  |  |  | (1,693) |
Stock-based compensation |  |  |  |  |  |  |  |  | (393) |
Centralized distribution costs |  |  |  |  |  |  |  |  | (1,609) |
Currency |  |  |  |  |  |  |  |  | 68 |
Restructuring and associated costs |  |  |  |  |  |  |  |  | (389) |
Acquisition and divestiture-related items |  |  |  |  |  |  |  |  | (777) |
Certain litigation charges, net |  |  |  |  |  |  |  |  | (149) |
Medical device regulations |  |  |  |  |  |  |  |  | (119) |
Income before income taxes |  |  |  |  |  |  |  |  | $ | 4,837 |
| Fiscal Year 2023
(in millions) | Cardiovascular |  | Neuroscience |  | Medical Surgical |  | Diabetes |  | Total
Net sales | $ | 11,522 |  |  | $ | 8,959 |  |  | $ | 7,989 |  |  | $ | 2,262 |  |  | $ | 30,731 |
Reconciliation of revenues |  |  |  |  |  |  |  |  |
Other operating segment net sales (1) |  |  |  |  |  |  |  |  | 495 |
Total consolidated net sales |  |  |  |  |  |  |  |  | $ | 31,227 |
Less: |  |  |  |  |  |  |  |  |
Cost of products sold, excluding amortization of intangible assets | 3,562 |  |  | 2,411 |  |  | 2,859 |  |  | 871 |  |  | 9,704 |
Research and development expense | 815 |  |  | 573 |  |  | 543 |  |  | 392 |  |  | 2,323 |
Selling, general, and administrative expense | 2,653 |  |  | 2,189 |  |  | 1,549 |  |  | 705 |  |  | 7,096 |
Other segment items (3) | (31) |  |  | 74 |  |  | (10) |  |  | (90) |  |  | (57) |
Reportable segment operating profit | $ | 4,522 |  |  | $ | 3,712 |  |  | $ | 3,048 |  |  | $ | 383 |  |  | $ | 11,664 |
Reconciliation of segment profit / (loss) |  |  |  |  |  |  |  |  |
Other operating segment loss (1) |  |  |  |  |  |  |  |  | (89) |
Corporate |  |  |  |  |  |  |  |  | (1,763) |
Interest expense, net |  |  |  |  |  |  |  |  | (636) |
Other non-operating income, net |  |  |  |  |  |  |  |  | 515 |
Amortization of intangible assets |  |  |  |  |  |  |  |  | (1,698) |
Stock-based compensation |  |  |  |  |  |  |  |  | (355) |
Centralized distribution costs |  |  |  |  |  |  |  |  | (1,558) |
Currency |  |  |  |  |  |  |  |  | 465 |
Restructuring and associated costs |  |  |  |  |  |  |  |  | (647) |
Acquisition and divestiture-related items |  |  |  |  |  |  |  |  | (345) |
Certain litigation charges, net |  |  |  |  |  |  |  |  | 30 |
Medical device regulations |  |  |  |  |  |  |  |  | (150) |
Commitments to the Medtronic Foundation and Medtronic LABS |  |  |  |  |  |  |  |  | (70) |
Income before income taxes |  |  |  |  |  |  |  |  | $ | 5,364 |
(1)Includes the operations and ongoing transition agreements from businesses the Company has exited or divested. (2)Includes incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. (3)Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular and Diabetes segments also include income from funded research and development arrangements.
Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated | Total Assets and Depreciation Expense
| Total Assets |  | Depreciation Expense
(in millions) | April 25, 2025 |  | April 26, 2024 |  | 2025 |  | 2024 |  | 2023
Cardiovascular | $ | 16,548 |  |  | $ | 16,128 |  |  | $ | 225 |  |  | $ | 199 |  |  | $ | 209 |
Neuroscience | 18,476 |  |  | 18,270 |  |  | 282 |  |  | 252 |  |  | 267 |
Medical Surgical | 33,317 |  |  | 33,586 |  |  | 205 |  |  | 194 |  |  | 203 |
Diabetes | 4,136 |  |  | 3,996 |  |  | 112 |  |  | 94 |  |  | 80 |
Total reportable segments | 72,476 |  |  | 71,980 |  |  | 823 |  |  | 739 |  |  | 759 |
Other operating segment (1) | 296 |  |  | 547 |  |  | 1 |  |  | — |  |  | 2 |
Corporate | 18,906 |  |  | 17,455 |  |  | 229 |  |  | 215 |  |  | 238 |
Total | $ | 91,680 |  |  | $ | 89,981 |  |  | $ | 1,054 |  |  | $ | 954 |  |  | $ | 999 |
(1)Includes the operations and ongoing transition agreements from businesses the Company has exited or divested.
Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region | The following table presents net sales for fiscal years 2025, 2024, and 2023, and property, plant, and equipment, net at April 25, 2025 and April 26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries:
| Net sales |  | Property, plant, and equipment, net
(in millions) | 2025 |  | 2024 |  | 2023 |  | April 25, 2025 |  | April 26, 2024
Ireland | $ | 116 |  |  | $ | 113 |  |  | $ | 98 |  |  | $ | 291 |  |  | $ | 252 |
United States | 17,171 |  |  | 16,562 |  |  | 16,373 |  |  | 5,133 |  |  | 4,593 |
Rest of world | 16,250 |  |  | 15,689 |  |  | 14,756 |  |  | 1,414 |  |  | 1,286 |
Total other countries, excluding Ireland | 33,421 |  |  | 32,251 |  |  | 31,129 |  |  | 6,547 |  |  | 5,879 |
Total | $ | 33,537 |  |  | $ | 32,364 |  |  | $ | 31,227 |  |  | $ | 6,837 |  |  | $ | 6,131 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration